



(51) International Patent Classification:

G01N 33/576 (2006.01) G06F 19/00 (2011.01)
G01N 33/92 (2006.01)

(21) International Application Number:

PCT/EP2017/073241

(22) International Filing Date:

15 September 2017 (15.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16306186.4 16 September 2016 (16.09.2016) EP

(71) Applicants: **BIOPREDICTIVE** [FR/FR]; 218 boulevard Saint-Germain, 75007 PARIS (FR). **ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS** [FR/FR]; 3, avenue Victoria, 75004 PARIS (FR).

(72) Inventor: **POYNARD, Thierry**; 10 rue Guynemer, 75006 PARIS (FR).

(74) Agent: **FLESSELLES, Bruno**; BF IP, 36 rue Jean de La Fontaine, 75016 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD OF DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASES

(57) Abstract: The present invention relates to new methods for assessing NAFLD and NAH in a patient, combining measurement of serum markers through a logistic function.



WO 2018/050804 A1

METHOD OF DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASES

5 The invention relates to a new non-invasive quantitative test making it possible to detect and help characterize subjects at risk of non-alcoholic fatty liver disease (NAFLD) and in particular those with non-alcoholic steato-hepatitis (NASH).

10 The tests as disclosed in the present application make it possible, in particular to identify among subjects at risk of non-alcoholic fatty liver disease (NAFLD),

- those with non-alcoholic steato-hepatitis (NASH) and
- those with clinically significant NAFLD disease (significant inflammation including NASH or significant fibrosis).

15

The solution provided by the present application lies in two new tests

- a non-invasive quantitative test (NIT) which makes it possible to determine whether a person at risk is to be treated or followed-up, assessing the severity of inflammation, independently of steatosis and fibrosis,
- a binary test which predicts histological significant NAFLD disease, combining inflammation (activity) and fibrosis and uses markers used in the NIT as disclosed above.

20

25 Background of the invention

Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver, occurring when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. NAFLD is the most common liver disorder in developed countries. NAFLD is a condition generally associated with factors of the metabolic syndrome.

30

While a liver may remain fatty without disturbing liver function, it may also progress to become non-alcoholic steatohepatitis (NASH), a state in which steatosis is combined with inflammation and fibrosis (steatohepatitis). NASH is a progressive disease: over a 10-year period, up to 20% of patients with NASH will develop cirrhosis of the liver, and 10% will suffer death related to liver disease.

35

Non-alcoholic steatohepatitis (NASH) is thus the most extreme form of NAFLD, and is regarded as a major cause of cirrhosis of the liver of unknown cause.

As indicated in Ratzu *et al* (2007, Aliment Pharmacol Ther 25, 207-218),
5 and Perazzo *et al* (2014, Aliment Pharmacol Ther 40:1081-93), there is a strong association between the number of metabolic risk factors and the prevalence of significant fibrosis presumed by FibroTest, which predicted overall survival in patients with type-2 diabetes and/or dyslipidemia.

In order to improve the outcome of the disease, it is important to be able to
10 detect it in the patients as early as possible as the outcome is good if the condition is detected and treated in its early stages. However, it is impossible to perform liver biopsy in such a large number of patients with metabolic risk factors to identify patients with advanced liver fibrosis or with steatohepatitis (non-alcoholic steatohepatitis, NASH).

15 It is thus important to be able to detect, especially among these patients, those having a liver disease (activity grade A2 or above or fibrosis stage F2 or above (according to SAF classification)) in order to be able to treat these patients or follow them up. Such detection should be reliable, non-invasive and as little expensive as possible as it is to be made on a large number of patients.

20

Current methods of diagnosis are measurement of elevated liver enzymes and/or liver ultrasound showing steatosis. An ultrasound may also be used to exclude gallstone problems (cholelithiasis). Liver biopsy (tissue examination) is the test widely accepted as definitively distinguishing NASH from other forms of liver
25 disease and can be used to assess the severity of the inflammation (activity scores) and resultant fibrosis.

Non-invasive diagnostic tests have been developed, such as FibroTest, that estimates liver fibrosis (Halfon *et al*, 2008), and SteatoTest, that estimates steatosis (Ratzu *et al*, 2006), however their use has not been widely adopted
30 (Vuppalanchi and Chalasani, 2009). Apoptosis has been indicated as a potential mechanism of hepatocyte injury as caspase-cleaved cytokeratin 18 (M30-Apoptosense ELISA) in serum/plasma is often elevated in patients with NASH and tests based on these parameters have been developed (Sowa *et al*, 2013). However, as the role of oncotic necrosis has yet to be examined it is unknown to
35 what degree apoptosis acts as the predominant form of injury (Feldstein *et al*, 2009; Musso *et al*, 2010).

Other diagnostic tests are available. Relevant blood tests include erythrocyte sedimentation rate, glucose, albumin, and kidney function. Because the liver is important for making proteins used in coagulation some coagulation related studies are often carried out especially the INR (international normalized ratio). In people with fatty liver with associated inflammatory injury (steatohepatitis) blood tests are usually used to rule out viral hepatitis (hepatitis A, B, C and herpes viruses like EBV or CMV), rubella, and autoimmune related diseases. Hypothyroidism is more prevalent in NASH patients which would be detected by determining the TSH (Liangpunsakul and Chalasani, 2003).

It has been suggested that in cases involving overweight patients whose blood tests do not improve on losing weight and exercising that a further search of other underlying causes is undertaken. This would also apply to those with fatty liver who are very young or not overweight or insulin-resistant. In addition, those whose physical appearance indicates the possibility of a congenital syndrome, have a family history of liver disease, have abnormalities in other organs, and those that present with moderate to advanced fibrosis or cirrhosis (Cassiman and Jaeken, 2008).

Previous most used non-invasive quantitative test (NIT) in patients with presumed NAFLD had limitations, including validations using histological reference mixing fibrosis, steatosis or activity (NAFLDscore, FIB4) or not continuous quantitative score (NashTest, BARD), and are mostly developed for Fibrosis (NAFLDscore, FIB4).

NashTest, developed by the BioPredictive (Paris, France) is diagnostic for non-alcoholic steato hepatitis (NASH) in patients with metabolic steatosis (overweight, diabetes, hyperlipidemia) and combines alpha2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, fasting glucose, triglycerides, cholesterol, ALT and AST, with parameters adjusted for patient's age, gender, weight and height.

The NAFLDscore (Angulo et al, Hepatology. 2007 Apr;45(4):846-54) uses the markers age, hyperglycemia, body mass index, platelet count, albumin, and AST/ALT ratio.

The BARD score (Cichoż-Lach et al, Med Sci Monit. 2012; 18(12): CR735–CR740) was composed of 3 variables: AST/ALT ratio ≥ 0.8 (2 points); a BMI ≥ 28 (1 point); and the presence of diabetes (1 point). The possible score ranges from 0 to

4 points. According to the results of Harrison et al., BARD scores equaling 0 or 1 are of high (96%) negative predictive value (NPV) for advanced fibrosis (Gut. 2008;57:1441-47).

The FIB4 index is based on age, aspartate and alanine aminotransferase and platelet counts. The formula is $(\text{Age} \times \text{AST}) / (\text{Platelets} \times (\text{sqr}(\text{ALT})))$.

However, so far, none of the above NITs makes it possible to detect patients with liver inflammation or significant NAFLD disease among the “at risk” population, and in particular NASH as histologically defined by Bedossa et al, using FLIP algorithm and SAF scoring system. (Hepatology 2012, Nov;56(5):1751-9; Hepatology 2014, Aug;60(2):565-75).

Furthermore, the previous NITs as disclosed above were not constructed according to several variability factors, that took into account the variability of histological references and the choices of appropriate cutoffs for biomarkers.

15

In view of the above, it is thus necessary to develop a new test that would make it possible to reliably detect liver disease and the need to engage in treatment or follow-up of a patient, in particular in people presenting a factor of metabolic syndrome (who are the people most at risk of having developing NAFLD), while limiting the risk of false-positive or false-negative hits.

The problem with people with metabolic syndrome is that all don't present a liver dysfunction that would lead to development of NAFLD and ultimately to NASH. As indicated above, in view of the number of people “at risk”, and of the risks associated with liver biopsy, it is further not possible to perform liver biopsies on all patients with a factor of metabolic syndrome (or presenting liver steatosis as detected by echography) in order to see whether they would present a NAFLD symptom and need treatment or follow-up.

It is further to be noted that there is no current gold standard to detect whether people have a NAFLD, as diagnostic is ultimately made by the physician in view of the observations made by the histologist, which are subject of variability linked to the samples actually observed and the classification eventually decided by the observer, also the SAF classification has greatly improved the classification and stratification of patients.

35 **Metabolic Syndrome**

Metabolic syndrome is associated with the risk of developing cardiovascular disease and type 2 diabetes. Some studies have shown the prevalence in the USA to be an estimated 34% of the adult population, and the prevalence increases with age.

5 Metabolic syndrome is the name for a group of risk factors that increases the risk for the patient to develop heart disease (such as coronary heart disease where plaque builds up inside the coronary arteries, chest pain, heart attack, heart damage, myocardial infarction...) and other health problems such as diabetes and strokes.

10 These factors are

(1) Abdominal (central) obesity (apple shape): overweight with adipose tissue accumulation particularly around the waist and trunk. Excess fat in the stomach area is a greater risk factor for heart disease than excess fat in other parts of the body, such as on the hips

15 (2) High serum triglycerides (without treatment)

(3) Low high-density lipoprotein (HDL) cholesterol level (without treatment)
HDL cholesterol helps clear whole cholesterol from arteries. A low HDL cholesterol level raises your risk for heart disease.

(4) Elevated blood pressure (without treatment). Blood pressure is the force
20 of blood pushing against the walls of arteries as the heart pumps blood. If this pressure rises and stays high over time, it can damage the heart and lead to plaque buildup.

(5) Elevated fasting plasma glucose (without treatment), insulin resistance, or prediabetes. This may be an early sign of diabetes.

25

In the present context, one would consider that a patient is "at risk" and thus within the population where the tests herein described are of great interest, if he presents at least one, or more generally at least two, preferably at least three of these five factors.

30

Clinical manifestations of metabolic syndrome could also include:

(6) Chest pains or shortness of breath: Suggesting the rise of cardiovascular and other complications

(7) *Acanthosis nigricans*, hirsutism, peripheral neuropathy, and retinopathy,
35 in particular in patients with insulin resistance and hyperglycemia or with diabetes mellitus

- (8) *Xanthomas* or *xanthelasmas*, especially in patients with severe dyslipidemia
(9) Hyperuricemia
(10) polycystic ovarian syndrome (in women)
5 (11) erectile dysfunction (in men)

Consequently, a patient considered "at risk" in the present context, *i.e.* a patient for which there is a benefit to perform the tests as herein described is a patient presenting at least one, preferably at least two, more preferably at least
10 three of the clinical features (1) to (11), and more preferably at least one of the clinical features (1) to (5), more preferably at least two, more preferably at least three of the clinical features (1) to (5).

The applicant followed an original and innovative strategy that made it
15 possible to identify some biochemical markers and to design a quantitative test and a qualitative test. This strategy was, in particular, based on a new definition of the patients for which treatment is to be initiated, or who need close follow-up, that differs from the one currently used in the art.

20 One must understand that the definition of NASH has evolved over time. It was first proposed that NASH patient would present macrovesicular steatosis, hepatocellular ballooning, lobular inflammation that included a component of PMN leukocytes and fibrosis.

It was then proposed that the main markers of NASH are macrovesicular
25 steatosis (at least 5 % of steatosis, as determined by the SAF method developed by Bedossa et al (see above)), hepatocellular ballooning, lobular inflammation that included a component of PMN leukocytes (Brunt et al, Int. J. Mol. Sci. 2016, 17, 97). Assessing the histological data of patients, the FLIP algorithm (Figure 1) provides a method to determine whether a patient presents a NASH or not (*i.e.*
30 whether treatment or follow-up should be initiated). However, the FLIP algorithm requires that the patient presents a Steatosis SAF-grade S1 or more, thereby excluding patients with SAF-grade S0 who could however present an elevated Activity SAF-grade, lobular inflammation or hepatocyte ballooning.

35 The inventor used original histological reference for the diagnosis of NASH and was able to demonstrate that it is important to rather focus on ballooning and

lobular inflammation, that are specific features of necro-inflammatory histological activity.

In fact, by taking in to account, or not, the various factors that are considered as being important for NASH, the inventor noted that presence of
5 steatosis is not a factor that is important to detect patients in need of treatment or follow-up but.

The inventor was thus able to design a new activity test that particularly adapted for patients "at risk", and in particular more adapted than the non-invasive test already disclosed in the prior art, ActiTest (Biopredictive, Paris, France). The
10 ActiTest is calculated using an original combination of six biochemical markers (alpha2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, GGT, and ALT, parameters adjusted for patient's age and gender), and makes it possible to obtain an index of necro inflammatory activity. However, since this test was designed in and validated for patients with chronic hepatitis C or B, who present a
15 high level of inflammatory activity, it is not sensible enough to be used as routine diagnostic in patients as herein contemplated, as the level of activity in these patients is usually not high enough to be detected by ActiTest.

The inventor thus proposes a new paradigm to decide if a patient presents
20 a significant liver disease and if he must be treated or particularly followed-up:

This new paradigm is equivalent to a new definition of that that would be that a patient is presenting a NASH if

- (1) the context is favorable: the patient presents at least one factor of the metabolic syndrome, and the patient doesn't present another liver risk
25 factor (such as viral hepatitis or alcoholism)
- (2) the patient presents an Activity equal or higher than grade 2 according to the SAF scoring system:
 - a. lobular inflammation (presence of necro-inflammatory lesions of grade ≥ 2 or
30 b. hepatocyte ballooning of grade ≥ 2 , or
c. ballooning=1 and lobular inflammation=1

This definition of a NASH disease is thus different from the one provided by Bedossa et al with the FLIP algorithm, as it doesn't take into account whether the
35 patient has liver steatosis. It is also easier than the NASH definition according to the FLIP algorithm, which has multiple branches of decisions (see Figure 1) and

may not be easily workable. Finally, by not using liver steatosis as a criteria for NASH (and a criteria to initiate follow-up or treatment), this definition would not let aside patient with significant activity (grade ≥ 2) or significant fibrosis (stage ≥ 2) but no steatosis.

5 Currently, the patients with significant activity or fibrosis but no steatosis, or patients with high lobular inflammation but no ballooning (or the opposite), may not be treated, as not included in the NASH definition that is currently recognized in the art. The new definition of NASH is thus more sensitive than the previous definition of NASH according to the FLIP algorithm that is considered to lead to a high
10 number of false-negative patients that are, however, of clinical significance.

 The “Metabolic-NASH-ActiTest” as designed by the inventor and herein described makes it possible to detect patients that present these characteristics and that can thus be qualified as NASH patients. It is to be noted that the test is a
15 quantitative test as will be described below.

 Using the same innovative definition of NASH (in particular exclusion of the factor “steatosis” from the definition of the disease) and the same markers that were used for designing the “Metabolic-NASH-ActiTest” disclosed below, the
20 inventor was able to design a further test that permits to predict significant NAFLD disease as defined by the SAF scoring system (A2 or F2) (“Metabolic-FibroActiTest”).

 In the context of the present disclosure, except if specifically indicated, inflammation, steatosis grades or fibrosis stages are evaluated using the SAF
25 classification as disclosed in the art and reminded in Example 1. The term “significant” is indicated for a stage or grade equal or higher than 2. Inflammation and activity are used interchangeably in the context of the present disclosure.

 In developing the assays herein described, the inventor selected a new
30 combination of 11 components, among 13 components possibly associated with NAFLD. In particular, the inventor was able to exclude the fasting glucose which need fasting before harvest of blood or plasma samples, as well as BMI (Body Mass Index) the reliability of which is arguable with several causes of assessment variability, both for height and weight measurements. The fact that these two
35 factors (that are used in the BARD score, NashTest and NAFLDscore) are excluded from the test herein disclosed will clearly simplify the access to care,

reproducibility of the data and thus reliability of the conclusions that can be drawn, only relying on directly and unambiguously measurable markers.

Finally, and most importantly, for the construction of the new test, various factors of variability were taken into account:

- (a) the choice of histological cutoff (percentage of hepatocytes with steatosis) for defining steatosis,
- (b) the inclusion or not of steatosis in the definition of NASH,
- (c) the inclusion of histological controls without NAFLD, without steatosis and activity.

Using this methodology, which had not been described before, to the knowledge of the applicant, made it possible to obtain a very robust test that would lead to reliable results and information.

15

In summary, the design of the tests as herein disclosed was made using various non-common features:

- a new definition of NASH that redefines the patients that need to be treated or followed-up
- exclusion of BMI and fasting glucose from the studied markers, in order to improve ease of use and reliability of the tests
- verification of the robustness of the test, by multiple tests by varying parameters
- inclusion of data from patients that had liver disease, but no steatosis or activity which permitted to increase the size of a control group for assessing the robustness of the tests specificity, that were generally not included in the design of the tests already disclosed

The present application thus discloses two tests useful for taking decision for clinicians. It is indeed to be noted that these tests provide information (an index) that the physician will use, in combination with the clinical context, to decide whether to further investigate the clinical state of the patient, whether to initiate treatment, or whether the patient's state doesn't necessitate treatment.

The applicant thus designed a first test that may be called “Metabolic-NASH-ActiTest”, a quantitative NIT (the output of which ranges from 0.00 to 1) of the necroinflammatory histological activity.

This test makes it possible to predict the presence of histological activity
 5 specific to NASH (ballooning and/or lobular inflammation) and combines the following 11 components:

- (1) alpha2-macroglobulin (A2M) (g / l)
- (2) Age (years)
- (3) alanine aminotransferase (ALT) (IU / l)
- 10 (4) apolipoprotein A-1 (Apoa1) (g / l)
- (5) Aspartate transaminase (also named aspartate aminotransferase, AST) (IU / l)
- (6) total bilirubin (BILI) ($\mu\text{mol/l}$)
- (7) cholesterol (CT) (mmol/l)
- 15 (8) Gender (0 for women, 1 for men)
- (9) gamma-glutamyl transpeptidase (GGT) (IU / l)
- (10) Haptoglobin (Hapto) (g / l)
- (11) Triglycerides (TG) (mmol/l).

20 The second test may be called “Metabolic-FibroActiTest” and is a binary test, permitting to predict significant liver disease (activity grade 2 or fibrosis stage 2) or mild NAFLD disease (no activity grade 2 and no fibrosis grade 2) and uses the same markers.

This second test can be written using the FibroTest®, a NIT extensively
 25 validated for the diagnostic and prognosis of fibrosis stages, as one of its components, with 4 other components associated not included in the FibroTest® panel but included in the “Metabolic-NASH-ActiTest” as disclosed herein: ALT, AST, cholesterol and triglycerides. This choice allowed to simplify the drafting of the “Metabolic-FibroActiTest” while preventing a co-linearity effect as some
 30 components of the Metabolic-NASH-ActiTest were already included in the FibroTest components: apolipoprotein A1, haptoglobin, alpha-2-macroglobulin, total bilirubin, GGT, age and gender.

This second test “Metabolic-FibroActiTest” share the common feature with the first test “Metabolic-NASH-ActiTest” as having been designed using the same
 35 innovative definition of liver disease that doesn’t make steatosis a prerequisite for a patient to be included in the definition.

It is reminded that FibroTest® is a universal validated fibrosis test widely disclosed in the art, and in particular in WO 2002/016949, and is marketed by the applicant Biopredictive (Paris, France).

5 The quality of a diagnosis test would generally be determined by drawing a Receiving Operating Characteristic (ROC) curve and measuring the Area Under Receiving Operating Characteristic curve (AUROC).

 The ROC curve is drawn by plotting the sensitivity versus (1-specificity), after classification of the patients, according to the result obtained for the diagnosis
10 test, for different thresholds (from 0 to 1).

 It is usually acknowledged that a ROC curve the area under which has a value superior to 0.7 is a good predictive curve for diagnosis. The ROC curve has to be acknowledged as a curve allowing prediction of the quality of a diagnosis test. It is best for the AUROC to be as closed as 1 as possible, this value
15 describing a test which is 100 % specific and sensitive.

 It is reminded that

 (1) sensitivity is the probability that the diagnosis is positive in individuals suffering from the disease sought (detection of true positives): the test is positive if the patient is suffering from the disease. The sensitivity is low
20 when the number of false negatives is high. The sensitivity is calculated by the formula $SE = (\text{number of individuals suffering from the disease in whom the sign is present}) / (\text{number of individuals suffering from the disease in whom the sign is present} + \text{number of individuals suffering from the disease in whom the sign is absent})$.

 (2) specificity is the probability that the diagnosis is negative in the individuals not suffering from the disease sought (non-detection of true negatives): the test is negative if the patient is not suffering from the disease. The specificity is low when the number of false positives is high. The specificity is calculated by the formula $SP = (\text{number of individuals not suffering from the disease in whom the sign is absent}) / (\text{number of individuals not suffering from the disease in whom the sign is absent} + \text{number of individuals not suffering from the disease in whom the sign is present})$.
30

 (3) Positive predictive value (PPV): is the probability of having the disease if the diagnostic test is positive (i.e. that the patient is not a false positive): the patient is suffering from the disease if the test is positive.
35

5 The positive predictive value is calculated by the formula $PPV = \frac{\text{(number of individuals suffering from the disease in whom the sign is present)}}{\text{(number of individuals suffering from the disease in whom the sign is present + number of individuals not suffering from the disease in whom the sign is present)}}$.

10 (4) Negative predictive value (NPV): is the probability of not having the disease if the diagnostic test is negative (that the patient is not a false negative): the patient is not suffering from the disease if the test is negative. The negative predictive value is calculated by the formula $NPV = \frac{\text{(number of individuals not suffering from the disease in whom the sign is absent)}}{\text{(number of individuals not suffering from the disease in whom the sign is absent + number of individuals suffering from the disease in whom the sign is absent)}}$.

15 In order to obtain a good diagnostic test, it is important to both increase specificity and sensitivity.

20 In developing the assays and tests as herein disclosed, the inventor increased the sensitivity of the test by defining NASH by the presence of either ballooning of the hepatocyte or lobular inflammation (rather than by the presence of these two elements further in the presence of steatosis). The inventor showed that a better AUROC was obtained by not using steatosis as a criterion for NASH.

25 Specificity was increased and verified by using "strong" negative controls such as patients who don't *a priori* have a liver condition (such as patients A0F0 according to the METAVIR classification) or may have presented a liver condition (such as liver activity or liver fibrosis) but that was clearly not linked to fatty disease (such as patients cured from hepatitis C, who don't have a metabolic syndrome: although these patients may have presented a beginning of fibrosis or liver activity that is not linked to NAFLD or NASH, they would thus be qualified as negative in the assay as herein disclosed).

30

Generally, a diagnosis (or diagnostic) method comprises

- 35 i. a step of gathering information from the patient
- ii. a step of comparing said information with regards to thresholds
- iii. a step of deducing, from the difference between the patient's information and the threshold, whether the patient has a specific disease or the stage of the patient's disease.

As a matter of illustration

- 5 i. the information that can be gathered from the patient can be gathered directly from the patient (such as images from NMR, scanner, radiography, contrast-enhanced computed tomography), or indirectly from the patient, such as from a biological sample that has been obtained from a patient (such as urine, blood sample..). The information can be presence (or absence) and/or level of specific biological markers, whether specific from the pathogenic determinant (bacterial or
- 10 viral DNA), or elevated levels of patient's markers
- 15 ii. once the information is obtained, it is compared to different values / standards and the deviation with regards to these standards is assessed. As a matter of illustration, the level of some biomarkers shall be compared to the level usually observed in healthy patients and to the levels usually observed in patients with the disease. Thresholds may exist, where 95 % of patients having passed the threshold have the disease and 95 % of the patients not having passed the threshold do not have the disease. For diseases where multiple clinical stages can be determined, such thresholds can discriminate the different
- 20 stages. In this step ii, one may compare various types of information to their respective standards, in order to be able to reach a diagnostic in step iii (as a matter of illustration, one can use the values and information obtained from measurement of various blood or plasma markers, images from scanner and of Body Mass Index).
- 25 iii. the last step is actually making the diagnosis i.e. deciding whether or not the patient has the condition sought, taking, in particular, into account the information gathered from the patient, the thresholds as described above. The physician may also take into account other elements (such as the consistency of the information gathered or the
- 30 like) to make the diagnostic.

Some diagnostic methods, such as the ones disclosed in the present application, shall also include a step i.a), which comprise the steps of modifying the information obtained from the patient in order to obtain a new type of information,

35 which is the one that is then compared to the standards in step ii.

It is further to be noted that the mere measurement of the values of levels of markers in the plasma or serum of a patient and the combination thereof in an algorithm as herein disclosed is part of a diagnostic method but only provides an intermediate result (an index) that would then to be compared to a reference index,
5 in order to actually be able to pose the diagnostic.

It is also to be noted that the tests herein disclosed are not “gold-standard” tests, in the sense that the output (index calculated by the formulas herein disclosed) isn’t a definitive answer as to the state of the patient. Indeed, these tests are based on statistics and there may thus be false-positive or false-negative
10 results, which is the reason why the specific experience of the physician in interpreting the index is of importance for reaching a diagnosis.

However, due to the specificity, sensitivity, positive predictive value and negative predictive value of the tests, herein provided for various thresholds of the index, these tests are of great interest in provided a help to the physician when
15 investigating a clinical case. Consequently, step iii as disclosed above is not direct and immediate from step ii, as the physician must interpret the result from the clinical and general context to be able to reach a diagnosis.

The invention relates to a method for developing a non-invasive diagnosis
20 test (comprising a logistic function, obtained by logistic regression analysis) for detecting NASH in a patient, or for obtaining a logistic function that can be used in a non-invasive diagnosis test for detecting NASH in a patient, wherein said logistic function combines the values of the concentration of biochemical markers in the serum of said patient, comprising the steps of:

- 25 a) classifying patients of a cohort of patients into different groups according to the presence of NASH as determined by analysis of liver biopsy, whereas a patient is classified as having NASH if he
- i. has at least one factor of the metabolic syndrome, and not any other chronic or acute liver disease and
 - 30 ii. presents hepatocyte ballooning or lobular activity (at least grade 1 each or at least grade 2 for one)
- b) identifying, among the biochemical markers, the value of which has been measured, the ones which differ significantly between these groups by unidimensional analysis

- c) performing a logistic regression analysis to assess the independent discriminative value of these markers identified in step b) for the diagnosis of NASH
- d) constructing the logistic function by combination of these identified independent factors

The same steps can be applied in a method for developing a non-invasive test that can be used for reaching the diagnosis of NASH in a patient, which is also encompassed within the invention. this test will help the physician reach the diagnosis

This method is thus based on the new definition of NASH by the inventor, as indicated above.

Presence of an acute or chronic liver disease in a patient may lead to an erroneous diagnosis when applying the NITs disclosed herein. Indeed, even if the patient presents a factor of metabolic syndrome, concomitant presence of the liver disease would likely shift the result of the test. Conclusion on the presence of NASH would thus be drawn for patient without such disease.

An acute or chronic liver disease that must be taken into consideration is preferably included in the group consisting of chronic hepatitis B, chronic hepatitis C, alcoholic liver disease (including liver fibrosis or cirrhosis), auto-immune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, extra hepatic cholestasis, liver cancer with necrosis or cholestasis, infectious cholangitis, acute steatosis of pregnancy, hepatitis related to medication, iron overload (hemochromatosis), Wilson disease and alpha 1-antitrypsin deficiency. Other liver diseases may be taken into consideration by the physician in order to decide the weight to give to the results of the tests herein disclosed and the conclusion to reach with regards to the NASH status of the patient.

Classification in step a) is performed by histological analysis of liver samples that have been obtained by liver biopsy for each patient of the cohort. The different groups are "patient with NASH disease" and "patient without NASH disease". As indicated above, patients that are classified in the first group are the ones that present either hepatocyte ballooning or lobular activity, with an activity grade (sum of the grade of ballooning and of the grade of lobular inflammation according to the SAF classification) equal or higher than 2.

Presence of liver steatosis alone is not considered as a criterion sufficient for inclusion within the "NASH disease" group. Absence of liver steatosis or level of steatosis below 1 % or 5 % is not considered as a criterion sufficient to exclude a patient from the "NASH disease" group if the patient presents either one of
 5 hepatocyte ballooning grade 2 or lobular activity grade 2, or at least grade 1 for both ballooning and lobular inflammation and has at least one factor of the metabolic syndrome.

In the method for developing such diagnostic test, one would prefer one or
 10 more of the following, in either combination:

- (a) in step a), to use a test cohort comprising at least 100 patients.
- (b) In the cohort of a), that at least 50% of the patients should be presenting at least one factor of metabolic syndrome (and thus at risk of having NASH), and not an exclusion factor (chronic or acute liver
 15 disease)
- (c) In the cohort of a), that at least 10% of the patients are patients who have no steatosis and no activity
- (d) The biochemical markers the concentration of which is measured are chosen in the group consisting of α 2-macroglobulin, AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gammaglutamyl transpeptidase), total bilirubin, haptoglobin, apoA1, triglycerides, total cholesterol, fasting glucose, γ -globulin, albumin, α 1-globulin, α 2-globulin, β -globulin, IL10, TGF- β 1, apoA2, apoB, cytokeratin 18 and cytokeratin 19 components, platelets number,
 20 prothrombin level, hyaluronic acid, urea, N-terminal of type III procollagen, Tissue inhibitor metalloproteinase type-1 (TIMP-1), type IV collagen (Coll IV) and osteoprotegerin
- (e) The biochemical markers the concentration of which is measured are chosen in the group consisting of α 2-macroglobulin, AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gammaglutamyl transpeptidase), total bilirubin, haptoglobin, apoA1, triglycerides, total cholesterol, fasting glucose
 30
- (f) at least 6, more preferably at least 7, more preferably at least 8, more preferably at least 9, biochemical markers are used in the logistic
 35 function of d)

- (g) The logistic function obtained in d) further includes at least one other variable chosen in the group consisting of gender, age and BMI of the patient
- (h) The logistic function does not comprise BMI
- 5 (i) The logistic function does not comprise fasting glucose
- (j) The method further comprises a step of validating the logistic function on a validation cohort comprising at least 100 patients;

In view of the above, it is to be understood that BMI and/or fasting glucose
 10 may or may not be included in the logistic function of d). The inventor showed below that it is possible not to include these two elements, but it is also possible to obtain a workable function that includes one or both of these markers.

Metabolic-NASH-ActiTest

15 The invention relates to an *in vitro* method for diagnosis of NASH in a patient comprising the step of:

- a) combining the values as measured from markers present in the serum or plasma of said patient through a logistic function, wherein said first logistic function is
- 20 $a1 + a2 \times \text{Log}(\text{A2M, g/l}) + a3 \times \text{Age (years)} + a4 \times \text{Log}(\text{ALT, IU / l}) + a5 \times \text{Log}(\text{Apoa1, g/l}) + a6 \times \text{Log}(\text{AST, IU/l}) + a7 \times \text{Log}(\text{BILI, } \mu\text{mol/l}) + a8 \times \text{Log}(\text{CT, mmol/l}) + a9 \times \text{Gender (0 for women, 1 for men)} + a10 \times \text{Log}(\text{GGT, IU / l}) + a11 \times \text{Log}(\text{Hapto, g/l}) + a12 \times \text{Log}(\text{TG, mmol/l})$

With

- 25 - $-8 \leq a1 \leq -7$
- $0.1 \leq a2 \leq 0.6$ preferably $0.15 \leq a2 \leq 0.55$
- $0.02 \leq a3 \leq 0.05$ preferably $0.03 \leq a3 \leq 0.04$
- $1.1 \leq a4 \leq 1.5$ preferably $1.2 \leq a4 \leq 1.4$
- $-0.2 \leq a5 \leq 1.0$
- 30 - $1.8 \leq a6 \leq 2.3$ preferably $1.95 \leq a6 \leq 2.2$
- $0.8 \leq a7 \leq 1.6$ preferably $0.9 \leq a7 \leq 1.5$
- $-1.7 \leq a8 \leq -1.3$ preferably $-1.6 \leq a8 \leq -1.4$
- $0.015 \leq a9 \leq 0.20$
- $0.15 \leq a10 \leq 0.25$ preferably $0.20 \leq a10 \leq 0.22$
- 35 - $-0.3 \leq a11 \leq 0.1$
- $0.9 \leq a12 \leq 1.2$ preferably $1.0 \leq a12 \leq 1.1$

In particular said logistic function is:

-7.82349 + 0.50879 x Log (A2M, g/l) + 0.036625 x Age (years) + 1.22544 x Log (ALT, IU/l) -0.12954 x (Apoa1, g/l) + 2.18581 x Log (AST, IU/l) + 1.48183 x Log (BILI, μ mol/l) -1.49351 x Log (CT, mmol/l) + 0.019536 Gender (0 for women, 1 for men) + 0.21614 x Log(GGT, IU / l) -0.026321 x Log (Hapto, g/l) + 1.09487 x Log (TG, mmol/l).

In another embodiment, said function is

-7.370196 + 0.18026 x Log (A2M, g/l) + 0.034609 x Age (years) + 1.47222 x Log (ALT, IU / l) + 0.089966 x (Apoa1, g/l) + 1.99317 x Log (AST, IU/l) + 0.98523 x Log (BILI, μ mol/l) -1.55580 x Log (CT, mmol/l) + 0.17857 x Gender (0 for women, 1 for men) + 0.020437 x Log(GGT, IU / l) + 0.055873 x Log (Hapto, g/l) + 1.00712 x Log (TG, mmol/l).

The coefficients of the formulas as provided above have been rounded to the 5th decimal.

Said method may also include the steps of obtaining (measuring) the different values used in the logistic function, such as the steps of measuring, in a blood or a plasma sample that have previously been harvested from the patient, the concentration / values / quantities of the various biological markers as mentioned above.

Said method may also include the steps of comparing the first index to a predetermined threshold, in particular to determine whether it is higher or lower than said threshold.

Said method may also include the step of deducing the presence of NASH in said patient if the first index is above said threshold.

The test as designed here is a quantitative test, the first index value ranging from 0 to 1. It is considered that a patient is likely to present a NASH disease (according to the definition herein provided) and would thus need a treatment or follow-up when the first index is equal or above 0.5.

It is to be noted that the test is quantitative. Consequently, the higher is the First Index, the more severe is the NASH disease. When the value of the First Index is around 0.5, the table above help take a decision on the diagnosis, but the general and specific clinical contexts must also be taken into consideration.

The invention also encompasses an *in vitro* method for obtaining a first index comprising the step of:

- 5 i. combining the values as measured from markers present in the serum or plasma of a patient through a logistic function, wherein said first logistic function is

$$a1 + a2 \times \text{Log (A2M, g/l)} + a3 \times \text{Age (years)} + a4 \times \text{Log (ALT, IU / l)} + a5 \times \text{Log (Apoa1, g/l)} + a6 \times \text{Log (AST, IU/l)} + a7 \times \text{Log (BILI, } \mu\text{mol/l)} + a8 \times \text{Log (CT, mmol/l)} + a9 \times \text{Gender (0 for women, 1 for men)} + a10 \times \text{Log (GGT, IU / l)} + a11 \times \text{Log (Hapto, g/l)} + a12 \times \text{Log (TG, mmol/l)}$$
- 10 With
 - $-8 \leq a1 \leq -7$
 - $0.1 \leq a2 \leq 0.6$ preferably $0.15 \leq a2 \leq 0.55$
 - $0.02 \leq a3 \leq 0.05$ preferably $0.03 \leq a3 \leq 0.04$
 - 15 - $1.1 \leq a4 \leq 1.5$ preferably $1.2 \leq a4 \leq 1.4$
 - $-0.2 \leq a5 \leq 1.0$
 - $1.8 \leq a6 \leq 2.3$ preferably $1.95 \leq a6 \leq 2.2$
 - $0.8 \leq a7 \leq 1.6$ preferably $0.9 \leq a7 \leq 1.5$
 - $-1.7 \leq a8 \leq -1.3$ preferably $-1.6 \leq a8 \leq -1.4$
 - 20 - $0.015 \leq a9 \leq 0.20$
 - $0.15 \leq a10 \leq 0.25$ preferably $0.20 \leq a10 \leq 0.22$
 - $-0.3 \leq a11 \leq 0.1$
 - $0.9 \leq a12 \leq 1.2$ preferably $1.0 \leq a12 \leq 1.1$
- 25 Preferred logistic functions for this embodiment are disclosed above.

The first index is usable for in a diagnostic method and will be used by the physician to eventually decide whether the patient presents or not a NASH, whether the patient needs to be treated or not, or further investigated. The decision from the physician will depend on the value of the index, as well as on other factors (general and specific medical context).

The invention also includes a device for diagnosis of NASH in a patient, comprising:

a) a first means, wherein the first means provides a first index by combining the values as measured from markers present in the serum or plasma of a patient through a logistic function, wherein said first logistic function is

$$a_1 + a_2 \times \text{Log (A2M, g/l)} + a_3 \times \text{Age (years)} + a_4 \times \text{Log (ALT, IU / l)} + a_5 \times \text{Log (Apoa1, g/l)} + a_6 \times \text{Log (AST, IU/l)} + a_7 \times \text{Log (BILI, } \mu\text{mol/l)} + a_8 \times \text{Log (CT, mmol/l)} + a_9 \times \text{Gender (0 for women, 1 for men)} + a_{10} \times \text{Log (GGT, IU / l)} + a_{11} \times \text{Log (Hapto, g/l)} + a_{12} \times \text{Log (TG, mmol/l)}$$

With

- $-8 \leq a_1 \leq -7$
- $0.1 \leq a_2 \leq 0.6$ preferably $0.15 \leq a_2 \leq 0.55$
- $0.02 \leq a_3 \leq 0.05$ preferably $0.03 \leq a_3 \leq 0.04$
- $1.1 \leq a_4 \leq 1.5$ preferably $1.2 \leq a_4 \leq 1.4$
- $-0.2 \leq a_5 \leq 1.0$
- $1.8 \leq a_6 \leq 2.3$ preferably $1.95 \leq a_6 \leq 2.2$
- $0.8 \leq a_7 \leq 1.6$ preferably $0.9 \leq a_7 \leq 1.5$
- $-1.7 \leq a_8 \leq -1.3$ preferably $-1.6 \leq a_8 \leq -1.4$
- $0.015 \leq a_9 \leq 0.20$
- $0.15 \leq a_{10} \leq 0.25$ preferably $0.20 \leq a_{10} \leq 0.22$
- $-0.3 \leq a_{11} \leq 0.1$
- $0.9 \leq a_{12} \leq 1.2$ preferably $1.0 \leq a_{12} \leq 1.1$.

Said first index can be later used to determine the presence of NASH in said patient and whether it is necessary to initiate treatment or follow-up, in particular using the help of table 1 above.

25

In a specific embodiment, the first mean is computerized. It may be an electronic spreadsheet with the formula recorded within, that provides the first index as an output when entering the various elements mentioned above. It can also be a computer program that provides the first index as an output after receipt of the various elements mentioned above.

The first means can present one or more of the following, in either combination:

- Operate within a private or public network
- Receive the inputs (values of the various elements mentioned above) from a sender that is in a remote place (i.e. they are sent to the first means from a different location than where the first means is located)

- Require the sender to identify himself before sending the inputs
- Receive the inputs (values of the various elements mentioned above) from a secure manner
- Send the output (first index) to the sender of the inputs
- 5 - Store the output in a database (possibly with a unique identifier, making it possible to assign inputs, outputs to this identifier)
- Provides the first index with further information (such as sensitivity and/or specificity and/or positive predictive value and/or negative predictive value linked to the prevalence of the condition in the
- 10 population to which belongs the patient)

Is also foreseen a non-transitory computer readable storage medium, having stored thereon a computer program comprising program instructions, the computer program being loadable into a data-processing unit and adapted to

15 cause the data-processing unit to carry out a method for calculating a first index by combining the values as measured from markers present in the serum or plasma of a patient through a logistic function as disclosed above, when the computer program is run by the data-processing device.

20 **Metabolic-FibroActiTest**

In the context of the present disclosure, a “significant” or “severe” NAFLD is defined as NAFLD with a SAF-Activity score ≥ 2 and/or a SAF-Fibrosis score ≥ 2 .

The invention also relates to an *in vitro* method for diagnosis of severity of NAFLD disease in a patient comprising the steps of :

- 25 a) combining the values as measured from markers present in the serum or plasma of said patient through a logistic function, wherein said first logistic function is

$$b1 + b2 \times \text{Log (A2M, g/l)} + b3 \times \text{Age (years)} + b4 \times \text{Log (ALT, IU / l)} + b5 \times (\text{Apoa1, g/l}) + b6 \times \text{Log (AST, IU/l)} + b7 \times \text{Log (BILI, } \mu\text{mol/l)} + b8 \times \text{Log (CT, mmol/l)} + b9 \times$$

30 Gender (0 for women, 1 for men) + b10 x Log(GGT, IU / l) + b11 x Log (Hapto, g/l) + b12 x Log (TG, mmol/l) in order to obtain a first index

With

- $-28 \leq b1 \leq -22$ preferably $-26 \leq b1 \leq -25$
- $13 \leq b2 \leq 19$ preferably $15 \leq b2 \leq 17$
- 35 - $0.05 \leq b3 \leq 0.15$ preferably $0.08 \leq a3 \leq 0.12$
- $0.9 \leq b4 \leq 1.4$ preferably $1.0 \leq b4 \leq 1.2$

- $-4.4 \leq b5 \leq -4.1$
- $2.4 \leq b6 \leq 2.7$ preferably $2.5 \leq b6 \leq 2.6$
- $6.0 \leq b7 \leq 6.4$ preferably $6.2 \leq b7 \leq 6.3$
- $-0.8 \leq b8 \leq -0.4$ preferably $-0.7 \leq b8 \leq -0.5$
- 5 - $1.0 \leq b9 \leq 1.1$
- $3.4 \leq b10 \leq 3.8$ preferably $3.6 \leq b10 \leq 3.7$
- $-5.0 \leq b11 \leq -4.5$ preferably $-4.9 \leq b11 \leq -4.8$
- $1.0 \leq b12 \leq 1.2$ preferably $1.05 \leq b12 \leq 1.15$

10 A preferred Metabolic-FibroActiTest formula is

- $25.98652 + 16.00374 \times \text{Log}(\text{Alpha2Macroglobulin (g/l)}) + 0.10067 \times \text{Age}$
(in years) + $1.12881 \times \text{Log (ALT, IU / l)} - 4.24187 \times \text{ApoA1 (g/l)} + 2.55422 \times \text{Log}$
(AST, IU / l) + $6.22308 \times \text{Log(Bilirubin (}\mu\text{mol/l)}) + 0.59340 \times \text{Log (CT, mmol/l)} +$
 $1.07838 \times \text{Sex (female=0, male=1)} + 3.64357 \times \text{Log(GGT (IU/l))} - 4.86167 \times$
15 $\text{Log(Haptoglobin (g/l))} + 1.11641 \text{ Log (TG, mmol/l)}.$

The coefficients of the formula as provided above have been rounded to the 5th decimal.

The above Metabolic-FibroActiTest can also be written as

- 20 $-6.13858 + 1.12881 \times \text{Log (ALT, IU / l)} + 2.55422 \times \text{Log (AST, IU / l)} -$
 $0.59340 \times \text{Log (CT, mmol/l)} + 3.58266 \times (4.467 \times \text{Log(Alpha2Macroglobulin (g/l)}) -$
 $1.357 \times \text{Log(Haptoglobin (g/l))} + 1.017 \times \text{Log(GGT (IU/l))} + 0.0281 \times \text{Age (in years)}$
 $+ 1.737 \times \text{Log(Bilirubin (}\mu\text{mol/l)}) - 1.184 \times \text{ApoA1 (g/l)} + 0.301 \times \text{Sex (female=0,$
 $\text{male=1)} - 5.540) + 1.11641 \text{ Log (TG, mmol/l)}.$

25

Consequently, the above Metabolic-FibroActiTest can also written as

- $-6.13858 + 1.12881 \times \text{Log (ALT, IU / l)} + 2.55422 \times \text{Log (AST, IU / l)} -$
 $0.59340 \times \text{Log (CT, mmol/l)} + 3.58266 \times \text{Fibrotest} + 1.11641 \text{ Log (TG, mmol/l)}$

- 30 where "Fibrotest" represents the value obtained after applying the
Fibrotest® test to the patient.

It is reminded that the formula for Fibrotest®, disclosed in WO 2002/016949, is $4.467 \times \text{Log(Alpha2Macroglobulin (g/l))} - 1.357 \times \text{Log(Haptoglobin (g/l))} + 1.017 \times \text{Log(GGT (IU/l))} + 0.0281 \times \text{Age (in years)} + 1.737 \times \text{Log(Bilirubin (}\mu\text{mol/l)}) - 1.184 \times \text{ApoA1 (g/l)} + 0.301 \times \text{Sex (female=0, male=1)} - 5.540$

35

The method can thus also be described as comprising a step of combining the values as measured from markers present in the serum or plasma of said patient through a logistic function, wherein said first logistic function is

$$c1 + c2 \times \text{Log (ALT, IU / l)} + c3 \times \text{Log (AST, IU/l)} + c4 \times \text{Log (CT, mmol/l)} + c5 \times$$

5 Fibrotest + $c6 \times \text{Log (TG, mmol/l)}$ in order to obtain a first index

With

- $-7 \leq c1 \leq -5$ preferably $-6.5 \leq c1 \leq -5.5$
- $0.9 \leq c2 \leq 1.4$ preferably $1.0 \leq c2 \leq 1.2$
- $2.4 \leq c3 \leq 2.7$ preferably $2.5 \leq c3 \leq 2.6$
- 10 - $-0.8 \leq c4 \leq -0.4$ preferably $-0.7 \leq c4 \leq -0.5$
- $3.0 \leq c5 \leq 4.2$ preferably $3.2 \leq c5 \leq 4.0$
- $1.0 \leq c6 \leq 1.2$ preferably $1.05 \leq c6 \leq 1.15$

Said method may also include the steps of obtaining (measuring) the
15 different values used in the logistic function, such as the steps of measuring, in a blood or a plasma sample that have previously been harvested from the patient, the concentration / values / quantities of the various biological markers as mentioned above.

Said method may also include the steps of comparing the final index to a
20 predetermined threshold, in particular to determine whether it is higher or lower than said threshold.

Said method may also include the step of deducing the severity of NAFLD in said patient if the final index is above said threshold. This deduction step shall be made by the physician, using in particular the information provided in Table 1.

25

Cutoff		Likelihood		Prev.	= 0.59
Value	Sensitivity	Specificity	Ratio	PPV	NPV
0.40	0.812	0.688	2.606	0.790	0.718
0.60	0.580	0.813	3.095	0.817	0.573

30

Table 1. Predictive Value Section for Severity using the Empirical ROC Curve for a prevalence of 0.59 (PPV: positive predictive valor; NPV: negative predictive valor).

In view of this table, it appears that an index below 0.40 would indicate that
35 the patient doesn't present a significant NAFLD (high sensitivity of the test), whereas an index above 0.60 would reflect presence of a significant NAFLD (high

specificity of the test). In any case, and as this test is not a gold-standard test, the physician would further use the global and specific clinical context to conclude, and especially when the index is between 0.40 and 0.60.

5 The invention also encompasses an *in vitro* method for obtaining a first index comprising the step of combining the values as measured from markers present in the serum or plasma of a patient through a logistic function, wherein said first logistic function is as disclosed above (Metabolic-FibroActiTest).

10 This first index would be used by the physician as a help to determine whether the patient suffers from significant NAFLD. This index is thus later used in a diagnostic method to determine the severity of NAFLD in said patient.

The invention also includes a device for diagnosis of severity of NAFLD in a patient, comprising:

15 a) a first means, wherein the first means provides a first index by combining the values as measured from markers present in the serum or plasma of a patient through a logistic function, wherein said first logistic function is as disclosed above (Metabolic-FibroActiTest)

20 In a specific embodiment, the first mean is computerized. It may be an electronic spreadsheet with the formula recorded within, that provides the first index as an output when entering the various elements mentioned above. It can also be a computer program that provides the first index as an output after receipt of the various elements mentioned above.

25 The first means can present one or more of the following, in either combination:

- Operate within a private or public network
- Receive the inputs (values of the various elements mentioned above) from a sender that is in a remote place (i.e. they are sent to the first means from a different location that where the first means is located)
- 30 - Require the sender to identify himself before sending the inputs
- Receive the inputs (values of the various elements mentioned above) from a secure manner
- Send the output (first index) to the sender of the inputs
- 35 - Store the output in a database (possibly with a unique identifier, making it possible to assign inputs, outputs to this identifier)

- Provides the first index with further information (such as sensitivity and/or specificity and/or positive predictive value and/or negative predictive value linked to the prevalence of the condition in the population to which belongs the patient)

5

Is also foreseen a non-transitory computer readable storage medium, having stored thereon a computer program comprising program instructions, the computer program being loadable into a data-processing unit and adapted to cause the data-processing unit to carry out a method for calculating a first index by
10 combining the values as measured from markers present in the serum or plasma of a patient through a logistic function as disclosed above, when the computer program is run by the data-processing device.

As indicated above, the methods and device of the invention are intended
15 to be used, preferably for patients presenting at least one factor of the metabolic syndrome.

It is further to be noted that the methods as disclosed reflect a level of injury of the liver (activity possibly coupled with fibrosis) and that diagnosis may be refined by any other methods, such as a liver biopsy in the patient to determine the
20 exact state of the liver.

The invention is also drawn to a kit of diagnosis of NASH and/or NAFLD in a patient, comprising instructions allowing to determine the presence of liver fibrosis and/or liver cirrhosis lesions in said patient, after dosage of the biochemical
25 markers, and measurement of liver stiffness.

The instructions comprise the various logistic functions that has to be used after determination of the dosage of the biochemical markers. It can appear as a printed support as well as a computer usable support, such as a software. The instructions may also comprise the threshold and tables that permit to obtain the
30 predictive values, depending of the expected prevalence of fibrosis in the patient population. It may also comprise reagents needed to measure the values of the various markers.

The following examples are meant to describe an aspect of invention, but
35 shall not be limiting the invention.

DESCRIPTION OF THE FIGURES

Figure 1: Diagnostic algorithm for NASH (from Bedossa et al, Hepatology, April 2014; Aug;60(2):565-75; doi: 10.1002/hep.27173)

Figure 2: Definitions of NASH according to the original FLIP algorithm and
5 according to three extended definitions: 27 combinations possible.

Figure 3: A. Comparison of AUROCS between Algo-9, ActiTest and FibroTest. B. Comparison of AUROCS between Algo-9 with standard blood tests: BARD, FIB4 and NAFLD-score

10 EXAMPLES

Example 1. Methods: SAF score and FLIP algorithm

The classification was performed according to the following criteria, with the following paragraphs directly extracted from Bedossa et al (Hepatology, April 2014; Aug;60(2):565-75; doi: 10.1002/hep.27173).

15 For each biopsy a SAF score (Steatosis, Activity, Fibrosis) summarizing the main histological lesions was defined. This assesses both and separately the grade of steatosis (S), the grade of activity (A) and the stage of fibrosis (F), the latter according to NASH CRN (Kleiner et al Hepatology 2005;41:1313-1321)

20 Steatosis was assessed by the percentage of hepatocytes containing large and medium-sized intracytoplasmic lipid droplets (but not foamy microvesicles), on a scale of 0 to 3 (S0: <5%; S1: 5%-33%, S2: 34%-66%, S3: >67%).

Ballooning of hepatocytes was graded from 0 to 2 (0: normal hepatocytes with cuboidal shape, sharp angles and pink eosinophilic cytoplasm; 1: presence of clusters of hepatocytes with a rounded shape and pale cytoplasm, usually
25 reticulated where although the shape is different, the size is similar to that of normal hepatocytes; 2, as for grade 1, but where there was also at least one enlarged ballooned hepatocyte (at least 2-fold size compared with that of normal cells within a cluster of hepatocytes with grade 1 ballooning).

Lobular inflammation was defined as a focus of two or more inflammatory
30 cells within the lobule organized either as microgranulomas or located within the sinusoids. Foci were counted at 20 X magnification (grade 0: none; 1: < 2 foci per lobule; 2: >2 foci per lobule).

The grade of activity (A from A0 to A4) was calculated by addition of grades of ballooning and lobular inflammation.

35

Then, the FLIP algorithm that enables dichotomous classification of a biopsy in either the steatosis without-NASH or the steatosis-with-NASH groups, was used. It is based on the semi-quantification of 3 elementary features, steatosis, clarification/ballooning of hepatocytes and lobular inflammation as evaluated
5 according to the SAF score.

For classification using the FLIP algorithm, steatosis was used as the criterion for entry into the algorithm weighted by hepatocellular ballooning and lobular inflammation. For any biopsy with at least grade 1 steatosis, the algorithm included 9 possible means of arriving at a decision. As described in Figure 1, a
10 case presenting with at least grade 1 of each of the three features (steatosis, ballooning, lobular inflammation) was classified as NASH. Other cases were diagnosed as steatosis (without NASH). Other histologic features possibly present in NASH were not considered for categorization.

15 **Example 2 – Methodology for developing the NASH-non-invasive test**

Recent simplified histological references were used for constructing new NITs, with modifications of these references due to the risk of sampling errors.

All histological scores were made according to the SAF classification as disclosed above.

20 For the binary histological diagnosis of NASH, it was decided to focus on ballooning and lobular inflammation, the specific features of necro-inflammatory histological activity as suggested by the histological FLIP algorithm. (Bedossa et al. Hepatology 2012, and Bedossa et al. Hepatology 2014).

It was indeed considered that the original FLIP algorithm has several
25 limitations, the arbitrary choice of 5% of hepatocytes steatosis defining presence of steatosis, the exclusion of cases without steatosis for the diagnostic of NASH despite the severe activity grades, and the arbitrary choice of requiring both ballooning and lobular inflammation even if one of this feature reached a grade 2.

These choices underestimate the risk of false negative of a biopsy, which
30 is not a perfect gold standard with significant risk due to sampling error (Ratziu 2005 Gastroenterology. 2005 Jun;128(7):1898-906).

Therefore, the performance of the new NITs was tested not only according to the original FLIP algorithm (named Histo-Algo-V1-S5) as reference, but also according to three other histological algorithms.

For the second algorithm (Histo-Algo-V2-S0), the definition of histological steatosis (for inclusion in the NAS-patients group) was steatosis equal or above 1% (rather than 5% in the original FLIP algorithm).

For the third algorithm, the definition of NASH did not require the presence of histological steatosis (Histo-Algo-V3-Sall-B1-L1).

For the the fourth algorithm (Histo-Algo-V4-Sall-B0F2B2F0), the definition of NASH did not require the presence of histological steatosis and also did not require the presence of both ballooning and lobular inflammation if one of this activity features was scored at least grade-2.

It results that the steatosis definition had two levels (above or the below the threshold that can be 0, 1 or 5 %), the grade of ballooning has 3 levels (SAF classification), the grade of lobular inflammation has 3 levels (SAF classification). Four (4) different algorithms were proposed for the diagnostic of NASH as indicated above;

The details of the 72 possible combinations of histological features (72 combinations= 2 levels x 3 levels x 3 levels x 4 algorithms) are described in Table 2.

Algorithm	Steatosis (S)	Ballooning	Lobular Inflammation	Classification as NASH or No-NASH based on Histology
Histo-Algo-V1-S5 (Standard reference, FLIP Algorithm)				
	S<5%	0	0	No-NASH
	S<5%	0	1	No-NASH
	S<5%	0	2	No-NASH
	S<5%	1	0	No-NASH
	S<5%	1	1	No-NASH
	S<5%	1	2	No-NASH
	S<5%	2	0	No-NASH
	S<5%	2	1	No-NASH
	S<5%	2	2	No-NASH
	S≥5%	0	0	No-NASH
	S≥5%	0	1	No-NASH
	S≥5%	0	2	No-NASH
	S≥5%	1	0	No-NASH
	S≥5%	1	1	NASH
	S≥5%	1	2	NASH
	S≥5%	2	0	No-NASH
	S≥5%	2	1	NASH
	S≥5%	2	2	NASH
Histo-Algo-V2-S0				
	S=0%	0	0	No-NASH
	S=0%	0	1	No-NASH

S=0%	0	2	No-NASH
S=0%	1	0	No-NASH
S=0%	1	1	No-NASH
S=0%	1	2	No-NASH
S=0%	2	0	No-NASH
S=0%	2	1	No-NASH
S=0%	2	2	No-NASH
S>0%	0	0	No-NASH
S>0%	0	1	No-NASH
S>0%	0	2	No-NASH
S>0%	1	0	No-NASH
S>0%	1	1	NASH
S>0%	1	2	NASH
S>0%	2	0	No-NASH
S>0%	2	1	NASH
S>0%	2	2	NASH
Histo-Algo-V3-noS-B1-L1			
S<5%	0	0	No-NASH
S<5%	0	1	No-NASH
S<5%	0	2	No-NASH
S<5%	1	0	No-NASH
S<5%	1	1	NASH
S<5%	1	2	NASH
S<5%	2	0	No-NASH
S<5%	2	1	NASH
S<5%	2	2	NASH
S≥5%	0	0	No-NASH
S≥5%	0	1	No-NASH
S≥5%	0	2	No-NASH
S≥5%	1	0	No-NASH
S≥5%	1	1	NASH
S≥5%	1	2	NASH
S≥5%	2	0	No-NASH
S≥5%	2	1	NASH
S≥5%	2	2	NASH
Histo-Algo-V4-noS-B0L2-B2L0			
S<5%	0	0	No-NASH
S<5%	0	1	No-NASH
S<5%	0	2	NASH
S<5%	1	0	No-NASH
S<5%	1	1	NASH
S<5%	1	2	NASH
S<5%	2	0	NASH
S<5%	2	1	NASH
S<5%	2	2	NASH
S≥5%	0	0	No-NASH
S≥5%	0	1	No-NASH
S≥5%	0	2	NASH
S≥5%	1	0	No-NASH
S≥5%	1	1	NASH
S≥5%	1	2	NASH
S≥5%	2	0	NASH
S≥5%	2	1	NASH

S≥5%	2	2	NASH
------	---	---	------

Table 2: Details of the 72 possible combinations of histological features: steatosis definition (two levels), grade of Ballooning (3 levels), grade of lobular inflammation (3 levels) and 4 different algorithms proposed for the diagnostic of

5 NASH after histological observation. 72 combinations= 2 levels x 3 levels x 3 levels x 4 algorithms. One will note that the conclusion on presence or absence of NASH is identical for the 9 first lines and the 9 last lines (respectively) of either or Histo-Algo-V3-noS-B1-L1 or Histo-Algo-V4-noS-B0L2-B2L0, due to the fact that presence or absence of steatosis is not taken into account to pose the NASH
10 diagnosis in these histological algorithms.

Figure 2 presents a summary of the extension of the definition of NASH, depending on the choice of the histological features taken into account for histological algorithms of Table 2.

15 **Example 3. Construction of the NIT-Algorithm for the diagnosis of NASH**

Choice of the markers to use in these NITs

It was decided to use ALT, AST, that are known biomarkers of liver necrosis, as well as eight other liver components synthesized by the liver :
20 apolipoprotein A1 (apoA1), haptoglobin, alpha-2-macroglobulin, total bilirubin, GGT, triglycerides, total cholesterol, fasting glucose and three patients characteristics (age, sex, and BMI).

Other markers could be equally used in the procedure herein described, such as markers that have been described in other liver NITs. One could cite γ-globulin, albumin, α1-globulin, α2-globulin, β-globulin, IL10, TGF-β1, apoA2, apoB,
25 cytokeratin 18 and cytokeratin 19 components, platelets number, prothrombin level, hyaluronic acid, urea, N-terminal of type III pro-collagen, Tissue inhibitor metalloproteinase type-1 (TIMP-1), type IV collagen (Coll IV) and osteoprotegerin.

However, it was decided to use only the 13 elements as mentioned above, as the result obtained already provides a test of good quality as observed by the
30 AUROC (see below), and as the markers selected by the inventors seem to be the most relevant in the clinical context. Furthermore, and even though there is no technical difficulties in measuring the plasma level of a large number of biomarkers, it was decided to limit the number of markers used, in particular for economic reasons.

Among the 13 components herein selected serum glucose which requires fasting by the patient for a reliable measure, and BMI which has several causes of measurements variability, are more complicated to collect than the 11 others.

Therefore, for each histological reference, the performances of the NIT-algorithms were significantly reduced using 11 versus 13 components, by modeling NITs that don't include these two markers.

NIT-Algorithms modeling

Eight NIT-Algorithms were constructed using regression analyses.

These eight NIT-Algorithms are obtained by using either the above 13 or 11 biomarkers and patient's characteristics for each of the 4 histological reference algorithms (that classify the patients as NASH or no-NASH patients, depending on the histological observations, as disclosed in example 2)

- NitAlgo-1-S5-13C was constructed using the original histological FLIP algorithm Histo-Algo-V1-S5 as reference, and using 13 components.
- NitAlgo-2-S5-11C was constructed using the original histological FLIP algorithm Histo-Algo-V1-S5 as reference, and using 11 components.
- NitAlgo-3-S0-13C was constructed using the algorithm Histo-Algo-V2-S0 as reference, and using 13 components.
- NitAlgo-4-S0-11C was constructed using the algorithm Histo-Algo-V2-S0 as reference, and using 11 components.
- NitAlgo-5-noS-13C was constructed using the algorithm Histo-Algo-V3-noS-B1-L1 as reference, and using 13 components.
- NitAlgo-5-noS-11C was constructed using the algorithm Histo-Algo-V3-noS-B1-L1 as reference, and using 11 components.
- NitAlgo-7-noS-13C was constructed using the algorithm Histo-Algo-V4-noS-B0F2-B2F0 as reference, and using 13 components.
- NitAlgo-8-noS-11C was constructed using the algorithm Histo-Algo-V4-noS-B0F2-B2F0 as reference, and using 11 components.

Results for the NASH-quantitative test for the diagnostic of NASH.

The performances of the above 8 NIT-algorithms varied not significantly from 0.711 (0.683-0.738) to 0.727 (0.699-0.753) for accuracy as well as for AUROC from 0.779 (0.751-0.807) to 0.796 (0.767-0.821).

Therefore, and for facilitating the access to care in the NAFLD context of use, this validated the choice to design algorithms without fasting glucose and BMI (11 components and not 13).

Algorithm NitAlgo-8-noS-11C presented the highest AUROC (0.796 (95% CI 0.767-0.821)) and Accuracy (0.722 (0.695-0.749)), as compared to the three others algorithms with 11 components (and the highest AUROC out of all the algorithms (13 or 11 components)).

For NitAlgo-8-noS-11C, the histological reference was a definition of NASH which doesn't not require steatosis and takes into account a grade 2 for Activity, either by grade 1 ballooning and lobular inflammation, or by grade 2 either ballooning alone or lobular inflammation alone (this NIT was obtained using the Histo-Algo-V4-noS-B0F2-B2F0 histological classification of patients).

The algorithm NitAlgo-2-S5-11C (which was designed using the histological Histo-Algo-V1-S5 classification of patients) makes it possible to help diagnosing presence or absence of NASH using the standard definition as made by the original and reference FLIP algorithm (requiring at least 5% steatosis and at least grade 1 for ballooning and for lobular inflammation).

20

Presumed by Blood tests	Biopsy FLIP algorithms			Accuracy	AUROC
	NASH	No-NASH	Total		
NIT-Algo-1-S5-13C (standard)	Histo-Algo-V1-S5				
NASH	407	166	573	0.715	0.785
No-NASH	142	366	508	(0.690-0.745)	(0.757-0.815)
Total	549	532	1081		
NIT-Algo-2-S5-11C	Histo-Algo-V1-S5				
NASH	400	158	558	0.716	0.780
No-NASH	149	374	523	(0.688-0.743)	(0.752-0.810)
Total	549	532	1081		
NIT-Algo-3-S0-13C	Histo-Algo-V2-S0				
NASH	407	165		0.715	0.784
No-NASH	143	366		(0.687-0.742)	(0.756-0.814)
Total	550	531	1081		
NIT-Algo-4-S0-11C	Histo-Algo-V2-S0				
NASH	398	159	557	0.712	0.779
No-NASH	152	372	524	(0.684-	(0.751-

				0.739)	0.807)
Total	550	531	1081		
NIT-Algo-5-noS-13C	Histo-Algo-V3-noS-B1-L1				
NASH	408	163	571	0.714	0.785
No-NASH	146	364	510	(0.686- 0.741)	(0.757- 0.813)
Total	554	527	1081		
NIT-Algo-6-noS-11C	Histo-Algo-V3-noS-B1-L1				
NASH	400	158	558	0.711	0.781
No-NASH	154	369	523	(0.683- 0.738)	(0.753- 0.809)
Total	554	527	1081		
NIT-Algo-7-noS-13C	Histo-Algo-V4-noS-B2L0-B0L2				
NASH	436	143	569	0.727	0.792
No-NASH	152	350	512	(0.699- 0.753)	(0.766- 0.818)
Total	588	493	1081		
NIT-Algo-8-noS-11C	Histo-Algo-V4-noS- B2L0-B0L2				
NASH	430	142	572	0.722	0.792
No-NASH	158	351	509	(0.695- 0.749)	(0.767- 0.821)
Total	588	493	1081		

Table 3: Regression analyses for the prediction of NASH, including 13 components or 11 components without BMI and fasting glucose.

- 5 NIT-Algo-8-noS-11C = $-7.82349 + 0.50879 \times \text{Log (A2M, g/l)} + 0.036625 \times \text{Age (years)} + 1.22544 \times \text{Log (ALT, IU / l)} - 0.12954 \times \text{Log (Apoa1, g/l)} + 2.18581 \times \text{Log (AST, IU / l)} + 1.48183 \times \text{Log (BILI, } \mu\text{mol/l)} - 1.49351 \times \text{Log (CT, mmol/l)} + 0.019536 + 0.21614 \times \text{Log (GGT, IU / l)} - 0.026321 \times \text{Log (Hapto, g/l)} + 1.09487 \times \text{Log (TG, mmol/l)}$.
- 10 Specificity, sensitivity, Positive predictive value (PPV) and negative predictive value (NPV) are proposed for three cutoffs (0.25, 0.50 and 0.75) and two prevalence of the disease (0.54 or 0.10), allowing to use the Metabolic-NASH-ActiTest (NIT-Algo-8-noS-11C) as an aid to decision. The corresponding predictive values were given in Tables 4 and 5.

15

NitAlgo8 Cutoff Value	Count + P A	Count + A B	Count - P C	Count - A D	Sensiti- vity A/(A+C)	False- C/(A+C)	False+ B/(B+D)	Specifi- city D/(B+D)
0.25	559	289	29	204	0.951	0.049	0.586	0.414

0.50	430	142	158	351	0.731	0.269	0.288	0.712
0.75	204	45	384	448	0.347	0.653	0.091	0.909

Table 4. ROC Data for Condition = HistoHalgoNASHV4 using the Empirical ROC Curve

NitAlgo8 Cutoff Value	Sensiti- vity	Specifi- city	Likeli- hood Ratio	Prev = PPV	0.54 NPV	Prev. = PPV	0.10 NPV
0.25	0.951	0.414	1.622	0.659	0.876	0.153	0.987
0.50	0.731	0.712	2.539	0.752	0.690	0.220	0.960
0.75	0.347	0.909	3.801	0.819	0.538	0.297	0.926

5

Table 5. Predictive Value Section for HistoHalgoNASHV4 using the Empirical ROC Curve

10 These tables can be used by the physician to reach a conclusion with regards to the status of the patient.

Another algorithm was developed and is of interest in the present context.

$$\text{NIT-Algo-2-S5-11C} = -7.370196 + 0.18026 \times \text{Log (A2M, g/l)} + 0.034609 \times \text{Age (years)} + 1.47222 \times \text{Log (ALT, IU / l)} + 0.089966 \times \text{Log (Apoa1, g/l)} + 1.99317 \times \text{Log (AST, IU/l)} + 0.98523 \times \text{Log (BILI, } \mu\text{mol/l)} - 1.55580 \times \text{Log (CT, mmol/l)} + 0.17857 \times \text{Gender (0 for women, 1 for men)} + 0.020437 \times \text{Log (GGT, IU / l)} + 0.055873 \times \text{Log (Hapto, g/l)} + 1.00712 \times \text{Log (TG, mmol/l)}.$$

15 This algorithm makes it possible to help diagnosing patients, according to the NASH definition of Bedossa et al (2014).

20

Example 5. Methodology for developing the “significant NAFLD” non-invasive test

Choice of histological reference for the binary diagnosis of “significant NAFLD”

25 For the binary definition of significant NAFLD, it was decided to rely on the definition as described by Bedossa et al (Bedossa et al Hepatology 2012 and Bedossa et al Hepatology 2014).

This algorithm is simple, a significant NAFLD being the presence of activity SAF-score ≥ 2 or a fibrosis SAF-score ≥ 2 . So far no other NIT has used this histological reference before.

Definition of significant fibrosis

For the histological diagnosis of significant fibrosis, the reference was the stage 2 being consensual in NAFLD, and similar for the SAF-fibrosis stage
 5 (Bedossa Hepatology 2012) than that of NASH-CRN staging (Kleiner Hepatology 2005).

Definition of significant activity

The FLIP definition of the histological diagnosis of significant activity was
 10 different than the FLIP definition of NASH grade-2 (Table 6).

The FLIP definition of the activity SAF-score for "significant activity" was simply the sum of ballooning and lobular-inflammation scores, without requiring presence of steatosis or of the presence of both ballooning and lobular inflammation.

15 In contrast, the FLIP definition of NASH required the presence of steatosis and presence of both ballooning and lobular inflammation.

Therefore, cases without steatosis (SAF-S0) can be classified as significant NAFLD due to Fibrosis stage F2 (SAF-F2).

20 Similarly, cases without ballooning but with grade 2 for lobular inflammation (or with ballooning grade 2 and no lobular inflammation) were classified SAF-A2 despite the absence of NASH using the FLIP algorithm.

Therefore, the reference for constructing the best NIT for the prediction of significant NAFLD was the presence of activity SAF-grade ≥ 2 or a fibrosis SAF score ≥ 2 named histological algorithm Histo-Algo-V5-S5-A2-F2.

25

Elementary features of NAFLD SAF scoring system				FLIP definition	
Steatosis	Activity		Fibrosis	NASH	Significant NAFLD
	Ballooning	Lobular Inflammation			
2 levels	3 levels	3 levels	2 levels	2 levels (yes = 1 / no = 0)	2 levels (yes = 1 / no = 0)
<5%	0	0	≤ 1	0	0
<5%	0	0	> 1	0	1
<5%	0	1	≤ 1	0	0
<5%	0	1	> 1	0	1
<5%	0	> 1	≤ 1	0	1
<5%	0	> 1	> 1	0	1
<5%	1	0	≤ 1	0	0

<5%	1	0	>1	0	1
<5%	1	1	<=1	0	1
<5%	1	1	>1	0	1
<5%	1	>1	<=1	0	1
<5%	1	>1	>1	0	1
<5%	2	0	<=1	0	1
<5%	2	0	>1	0	1
<5%	2	1	<=1	0	1
<5%	2	1	>1	0	1
<5%	2	>1	<=1	0	1
<5%	2	>1	>1	0	1
>=5%	0	0	<=1	0	0
>=5%	0	0	>1	0	1
>=5%	0	1	<=1	0	0
>=5%	0	1	>1	0	1
>=5%	0	>1	<=1	0	1
>=5%	0	>1	>1	0	1
>=5%	1	0	<=1	0	0
>=5%	1	0	>1	1	1
>=5%	1	1	<=1	1	1
>=5%	1	1	>1	1	1
>=5%	1	>1	<=1	1	1
>=5%	1	>1	>1	1	1
>=5%	2	0	<=1	0	1
>=5%	2	0	>1	0	1
>=5%	2	1	<=1	1	1
>=5%	2	1	>1	1	1
>=5%	2	>1	<=1	1	1
>=5%	2	>1	>1	1	1

Table 6: Algorithms for the definition of NASH and significant NAFLD

Among the 36 combinations, 9 (25%) will correspond to the FLIP definition
 5 of NASH, and 30 (83%) will correspond to the definition of significant NAFLD.

If Steatosis was defined as 1% and not 5% as defined by the standard
 algorithm, it is expected that the number of NASH and significant NAFLD cases will
 increase proportionally to the prevalence of steatosis 1-4% in the population of
 interest.

10

Example 6 Construction of the NIT-Algorithms for the diagnosis of significant NAFLD

Choice of components

The NitAlgo-9 algorithm combined the FibroTest®, a NIT extensively
 15 validated for the diagnostic and prognosis of fibrosis stages, with 4 components
 associated with activity, not included in the FibroTest® panel but included in the

NIT-Algorithms for the diagnostic of NASH: ALT, AST, cholesterol and triglycerides (Table 4).

5 This choice permitted to prevent a co-linearity effect as the other components used in the NASH algorithms described in example 4 were already included in the FibroTest® components: apolipoprotein A1, haptoglobin, alpha-2-macroglobulin, total bilirubin, GGT, age and gender.

NIT-Algo-9 algorithm modeling.

10 The NitAlgo-9 algorithm for the diagnosis of significant NAFLD was constructed using the original FLIP algorithm Histo-Algo-V5-S5-A2-F2 as the reference for histological significant NAFLD, and including 5 components: FibroTest and ALT, AST, cholesterol and triglycerides. (Table 4)

15 NAFLD severity algorithm for the prediction of significant NAFLD disease

According to SAF activity grading the prevalence of histological significant activity (A2A3A4) was $588/1081 = 54.4\%$ and significant fibrosis was $340/1081=31.5\%$. The prevalence of histological significant NAFLD combining SAF-Activity A2A3A4 or SAF-Fibrosis F2F3F4 = $638/1081 = 59.0\%$.

20 The performance of the NitAlgo-9 algorithm combining the FibroTest, ALT, AST, cholesterol and triglycerides was highly significant with AUROC= 0.811 and accuracy =0.732 (Table 7).

Presumed by	Biopsy FLIP algorithms			Accuracy	AUROC
Blood tests					
	Significant	Not Significant	Total		
NIT-Algo-9-A2F2 (standard)	Histo-Algo-V5-noS-A2F2				
Significant	453	105	558	0.732	0.814
Not Significant	185	338	523	(0.704-0.758)	(0.786-0.839)
Total	638	443	1081		

Table 7: Regression analyses for the prediction of significant NAFLD, including four components: FibroTest, ALT, AST, cholesterol and triglycerides. The histological reference was Histo-Algo-V5- S5A2F2.

5 Performance of Comparisons of algorithms with standard comparators: BARD, FIB4 and NAFLD-score (Table 5)

A total of 574 subjects had simultaneous measurements of NitAlgo-9 algorithm and BARD, FIB4 and NAFLD-score.(Tables 8.A and B)

Criterion	Empirical Estimate of AUC	AUC's Standard Error	Z-Value to Test AUC > 0.5	1-Sided Prob Level	2-Sided Prob Level	Prevalence Of Severity	Count
NAFLDf-score	0.570	0.030	2.38	0.0086	0.0172	0.814	574
FIB4	0.528	0.030	0.93	0.1769	0.3538	0.814	574
BARD	0.541	0.031	1.29	0.0990	0.1980	0.814	574
Algo9	0.675	0.029	6.14	0.0000	0.0000	0.814	574

10 Table 8.A Empirical Area Under Curve Analysis for Condition = Severity

Criteria 1,2	AUC1	AUC2	Value	Difference Std Error	Difference Percent	Z-Value	Prob Level
Algo9, NAFLDf-score	0.675	0.570	0.105	0.040	-15.54	2.63	0.0086
Algo9, FIB4	0.675	0.528	0.148	0.043	-21.88	3.40	0.0007
Algo9, BARD	0.675	0.541	0.135	0.046	-19.98	2.90	0.0037

Table 8.B Empirical Test of (AUC1 - AUC2) = 0 for Condition = Severity

Table 8: Comparison with other blood tests: BARD, FIB4 and NAFLD-score

15 The AUROC of algorithm NitAlgo9 (Metabolic-FibroActiTest) is also better than the one for these tests (Figure 3.B).

The algorithm NitAlgo9 (Metabolic-FibroActiTest) further permitted to obtain significantly higher AUROCs than FibroTest and ActiTest, for the diagnostic of

significant Metabolic Liver Disease as defined histologically by Bedossa et (SAF score F2 or A2) (Figure 3.A).

Specificity, sensitivity, Positive predictive value (PPV) and negative predictive value (NPV) are proposed for three cutoffs (0.25, 0.50 and 0.75) and two prevalence of the disease (0.59 or 0.10), to use the Metabolic-FibroActiTest as an aid to decision. The corresponding predictive values were given in Tables 9 and 10 (see also table 1).

NitAlgo9 Cutoff Value	Count + P A	Count + A B	Count - P C	Count - A D	Sensitivity A/(A+C)	False-C C/(A+C)	False+ B/(B+D)	Specificity D/(B+D)
0.25	607	241	31	202	0.951	0.049	0.544	0.456
0.50	453	105	185	338	0.710	0.290	0.237	0.763
0.75	261	44	377	399	0.409	0.591	0.099	0.901

Table 9. ROC Data for Condition = Significant disease using the Empirical ROC Curve

NitAlgo9 Cutoff Value	Sensitivity	Specificity	Likelihood Ratio	Prev = 0.59 PPV	NPV	Prev. = 0.10 PPV	NPV
0.25	0.951	0.456	1.749	0.716	0.867	0.163	0.988
0.50	0.710	0.763	2.996	0.812	0.646	0.250	0.959
0.75	0.409	0.901	4.119	0.856	0.514	0.314	0.932

Table 10. Predictive Value Section for Significant disease using the Empirical ROC Curve

Example 7 - Validation of NITs

The NITs were validated independently in 95 new NAFLD with biopsy and applied in a low risk population of 7,416 healthy volunteers (validation group). They were also applied to 79,955 subjects presumed NAFLD of a USA NASH-FibroSure database.

In the validation group, both NIT-A2F2 and NIT-NASH reached high positive predictive value, 81/85 (95.3%;88.4-98.7) and 82/88 (93.2%;87.9-98.4) for the diagnostic of NASH and significant disease respectively.

According to the definition of the disease, the prevalence of NASH varied ($P < 0.0001$) from 0.8% ($n=59$) to 17.8% ($n=1,317$) in the healthy cases, and in USA database from 16.3% ($n=13029$) to 61.6% ($n=49251$).

5 References

- Angulo et al, *Hepatology*. 2007 Apr;45(4):846-54
- Bedossa et al, *Hepatology*. 2012 Nov;56(5):1751-9. doi: 10.1002/hep.25889.
- Bedossa et al, *Hepatology*, April 2014; Aug;60(2):565-75; doi: 10.1002/hep.27173
- Brunt et al, *Int. J. Mol. Sci.* 2016, 17, 97
- 10 Cassiman D, Jaeken J (2008). "NASH may be trash". *Gut*. 57 (2): 141–4.
- Cichoż-Lach et al, *Med Sci Monit*. 2012; 18(12): CR735–CR740
- Feldstein et al (2009). "Cytokeratin-18 fragment levels as noninvasive biomarker for nonalcoholic steatohepatitis: A multicenter validation study". *Hepatology*. 50 (4): 1072–8.
- 15 Halfon et al (2008). "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". *Gastroenterol Clin Biol*. 32 (6): 22–39.)
- Kleiner et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41:1313-1321
- Liangpunsakul S, Chalasani N (2003). "Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?". *J Clin Gastroenterol*. 37 (4): 340–3.
- 20 Musso et al (2010). "Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity". *Annals of Medicine*. 43 (8): 1-33
- Perazzo et al (2014, *Aliment Pharmacol Ther* 40:1081-93)
- 25 Ratziu et al, 2005 *Gastroenterology*. 2005 Jun;128(7):1898-906
- Ratziu et al (2006). "Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease". *BMC Gastroenterology*. 6: 6.
- Ratziu et al, 2007, *Aliment Pharmacol Ther* 25, 207-218)
- 30 Sowa et al (2013). "Novel algorithm for non-invasive assessment of fibrosis in NAFLD.". *PLOS ONE*. 8 (4)
- Vuppalanchi R, Chalasani N (2009). "Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Selected practical issues in their evaluation and management". *Hepatology*. 49 (1): 306–317

Claims

1. An *in vitro* method for diagnosis of NASH in a patient comprising the step of:
 - a) combining the values as measured from markers present in the serum or plasma of said patient through a logistic function, wherein said first logistic function is $a_1 + a_2 \times \text{Log (A2M, g/l)} + a_3 \times \text{Age (years)} + a_4 \times \text{Log (ALT, IU / l)} + a_5 \times \text{(Apoa1, g/l)} + a_6 \times \text{Log (AST, IU/l)} + a_7 \times \text{Log (BILI, } \mu\text{mol/l)} + a_8 \times \text{Log (CT, mmol/l)} + a_9 \times \text{Gender (0 for women, 1 for men)} + a_{10} \times \text{Log(GGT, IU / l)} + a_{11} \times \text{Log (Hapto, g/l)} + a_{12} \times \text{Log (TG, mmol/l)}$ wherein
 - i. $-8 \leq a_1 \leq -7$
 - ii. $0.1 \leq a_2 \leq 0.6$ preferably $0.15 \leq a_2 \leq 0.55$
 - iii. $0.02 \leq a_3 \leq 0.05$ preferably $0.03 \leq a_3 \leq 0.04$
 - iv. $1.1 \leq a_4 \leq 1.5$ preferably $1.2 \leq a_4 \leq 1.4$
 - v. $-0.2 \leq a_5 \leq 1.0$
 - vi. $1.8 \leq a_6 \leq 2.3$ preferably $1.95 \leq a_6 \leq 2.2$
 - vii. $0.8 \leq a_7 \leq 1.6$ preferably $0.9 \leq a_7 \leq 1.5$
 - viii. $-1.7 \leq a_8 \leq -1.3$ preferably $-1.6 \leq a_8 \leq -1.4$
 - ix. $0.015 \leq a_9 \leq 0.20$
 - x. $0.15 \leq a_{10} \leq 0.25$ preferably $0.20 \leq a_{10} \leq 0.22$
 - xi. $-0.3 \leq a_{11} \leq 0.1$
 - xii. $0.9 \leq a_{12} \leq 1.2$ preferably $1.0 \leq a_{12} \leq 1.1$.
2. The *in vitro* method of claim 1, wherein the logistic function is $-7.82349 + 0.50879 \times \text{Log (A2M, g/l)} + 0.036625 \times \text{Age (years)} + 1.22544 \times \text{Log (ALT, IU/l)} - 0.12954 \times \text{(Apoa1, g/l)} + 2.18581 \times \text{Log (AST, IU/l)} + 1.48183 \times \text{Log (BILI, } \mu\text{mol/l)} - 1.49351 \times \text{Log (CT, mmol/l)} + 0.019536 \times \text{Gender (0 for women, 1 for men)} + 0.21614 \times \text{Log(GGT, IU / l)} - 0.026321 \times \text{Log (Hapto, g/l)} + 1.09487 \times \text{Log (TG, mmol/l)}$.
3. The *in vitro* method of claim 1, wherein the logistic function is $-7.370196 + 0.18026 \times \text{Log (A2M, g/l)} + 0.034609 \times \text{Age (years)} + 1.47222 \times \text{Log (ALT, IU / l)} + 0.089966 \times \text{(Apoa1, g/l)} + 1.99317 \times \text{Log (AST, IU/l)} + 0.98523 \times \text{Log (BILI, } \mu\text{mol/l)} - 1.55580 \times \text{Log (CT, mmol/l)} + 0.17857 \times \text{Gender (0 for women, 1 for men)} + 0.020437 \times \text{Log(GGT, IU / l)} + 0.055873 \times \text{Log (Hapto, g/l)} + 1.00712 \times \text{Log (TG, mmol/l)}$.

4. a device for diagnosis of NASH in a patient, comprising a first means, wherein the first means provides a first index by combining the values as measured from markers present in the serum or plasma of a patient through a logistic function, wherein said first logistic function is $a_1 + a_2 \times \text{Log (A2M, g/l)} + a_3 \times \text{Age (years)} + a_4 \times \text{Log (ALT, IU / l)} + a_5 \times \text{(Apoa1, g/l)} + a_6 \times \text{Log (AST, IU/l)} + a_7 \times \text{Log (BILI, } \mu\text{mol/l)} + a_8 \times \text{Log (CT, mmol/l)} + a_9 \times \text{Gender (0 for women, 1 for men)} + a_{10} \times \text{Log(GGT, IU / l)} + a_{11} \times \text{Log (Hapto, g/l)} + a_{12} \times \text{Log (TG, mmol/l)}$ wherein
- 10 i. $-8 \leq a_1 \leq -7$
 ii. $0.1 \leq a_2 \leq 0.6$ preferably $0.15 \leq a_2 \leq 0.55$
 iii. $0.02 \leq a_3 \leq 0.05$ preferably $0.03 \leq a_3 \leq 0.04$
 iv. $1.1 \leq a_4 \leq 1.5$ preferably $1.2 \leq a_4 \leq 1.4$
 v. $-0.2 \leq a_5 \leq 1.0$
 15 vi. $1.8 \leq a_6 \leq 2.3$ preferably $1.95 \leq a_6 \leq 2.2$
 vii. $0.8 \leq a_7 \leq 1.6$ preferably $0.9 \leq a_7 \leq 1.5$
 viii. $-1.7 \leq a_8 \leq -1.3$ preferably $-1.6 \leq a_8 \leq -1.4$
 ix. $0.015 \leq a_9 \leq 0.20$
 x. $0.15 \leq a_{10} \leq 0.25$ preferably $0.20 \leq a_{10} \leq 0.22$
 20 xi. $-0.3 \leq a_{11} \leq 0.1$
 xii. $0.9 \leq a_{12} \leq 1.2$ preferably $1.0 \leq a_{12} \leq 1.1$.
5. The device of claim 4, wherein the logistic function is $-7.82349 + 0.50879 \times \text{Log (A2M, g/l)} + 0.036625 \times \text{Age (years)} + 1.22544 \times \text{Log (ALT, IU/l)} - 0.12954 \times \text{(Apoa1, g/l)} + 2.18581 \times \text{Log (AST, IU/l)} + 1.48183 \times \text{Log (BILI, } \mu\text{mol/l)} - 1.49351 \times \text{Log (CT, mmol/l)} + 0.019536 \times \text{Gender (0 for women, 1 for men)} + 0.21614 \times \text{Log(GGT, IU / l)} - 0.026321 \times \text{Log (Hapto, g/l)} + 1.09487 \times \text{Log (TG, mmol/l)}$.
- 25
- 30 6. The device of claim 4, wherein the logistic function is $-7.370196 + 0.18026 \times \text{Log (A2M, g/l)} + 0.034609 \times \text{Age (years)} + 1.47222 \times \text{Log (ALT, IU / l)} + 0.089966 \times \text{(Apoa1, g/l)} + 1.99317 \times \text{Log (AST, IU/l)} + 0.98523 \times \text{Log (BILI, } \mu\text{mol/l)} - 1.55580 \times \text{Log (CT, mmol/l)} + 0.17857 \times \text{Gender (0 for women, 1 for men)} + 0.020437 \times \text{Log(GGT, IU / l)} + 0.055873 \times \text{Log (Hapto, g/l)} + 1.00712 \times \text{Log (TG, mmol/l)}$.
- 35

7. An *in vitro* method for diagnosis of severity of NAFLD disease in a patient comprising the steps of :
- a) combining the values as measured from markers present in the serum or plasma of said patient through a logistic function, wherein said first logistic function is $b_1 + b_2 \times \text{Log}(\text{A2M, g/l}) + b_3 \times \text{Age (years)} + b_4 \times \text{Log}(\text{ALT, IU / l}) + b_5 \times (\text{Apoa1, g/l}) + b_6 \times \text{Log}(\text{AST, IU/l}) + b_7 \times \text{Log}(\text{BILI, } \mu\text{mol/l}) + b_8 \times \text{Log}(\text{CT, mmol/l}) + b_9 \times \text{Gender (0 for women, 1 for men)} + b_{10} \times \text{Log}(\text{GGT, IU / l}) + b_{11} \times \text{Log}(\text{Hapto, g/l}) + b_{12} \times \text{Log}(\text{TG, mmol/l})$ in order to obtain a first index wherein
- i. $-28 \leq b_1 \leq -22$ preferably $-26 \leq b_1 \leq -25$
 - ii. $13 \leq b_2 \leq 19$ preferably $15 \leq b_2 \leq 17$
 - iii. $0.05 \leq b_3 \leq 0.15$ preferably $0.08 \leq a_3 \leq 0.12$
 - iv. $0.9 \leq b_4 \leq 1.4$ preferably $1.0 \leq b_4 \leq 1.2$
 - v. $-4.4 \leq b_5 \leq -4.1$
 - vi. $2.4 \leq b_6 \leq 2.7$ preferably $2.5 \leq b_6 \leq 2.6$
 - vii. $6.0 \leq b_7 \leq 6.4$ preferably $6.2 \leq b_7 \leq 6.3$
 - viii. $-0.8 \leq b_8 \leq -0.4$ preferably $-0.7 \leq b_8 \leq -0.5$
 - ix. $1.0 \leq b_9 \leq 1.1$
 - x. $3.4 \leq b_{10} \leq 3.8$ preferably $3.6 \leq b_{10} \leq 3.7$
 - xi. $-5.0 \leq b_{11} \leq -4.5$ preferably $-4.9 \leq b_{11} \leq -4.8$
 - xii. $1.0 \leq b_{12} \leq 1.2$ preferably $1.05 \leq b_{12} \leq 1.15$.
8. The *in vitro* method of claim 7, wherein the logistic function is $-25.98652 + 16.00374 \times \text{Log}(\text{Alpha2Macroglobulin (g/l)}) + 0.10067 \times \text{Age (in years)} + 1.12881 \times \text{Log}(\text{ALT, IU / l}) - 4.24187 \times \text{ApoA1 (g/l)} + 2.55422 \times \text{Log}(\text{AST, IU / l}) + 6.22308 \times \text{Log}(\text{Bilirubin (} \mu\text{mol/l)}) + 0.59340 \times \text{Log}(\text{CT, mmol/l}) + 1.07838 \times \text{Sex (female=0, male=1)} + 3.64357 \times \text{Log}(\text{GGT (IU/l)}) - 4.86167 \times \text{Log}(\text{Haptoglobin (g/l)}) + 1.11641 \text{Log}(\text{TG, mmol/l})$.
9. A device for diagnosis of severity of NAFLD in a patient, comprising a first means, wherein the first means provides a first index by combining the values as measured from markers present in the serum or plasma of a patient through a logistic function, wherein said first logistic function is $b_1 + b_2 \times \text{Log}(\text{A2M, g/l}) + b_3 \times \text{Age (years)} + b_4 \times \text{Log}(\text{ALT, IU / l}) + b_5 \times (\text{Apoa1, g/l}) + b_6 \times \text{Log}(\text{AST, IU/l}) + b_7 \times \text{Log}(\text{BILI, } \mu\text{mol/l}) + b_8 \times \text{Log}(\text{CT, mmol/l}) + b_9 \times \text{Gender (0$

for women, 1 for men) + $b_{10} \times \text{Log}(\text{GGT, IU / l}) + b_{11} \times \text{Log}(\text{Hapto, g/l}) + b_{12} \times \text{Log}(\text{TG, mmol/l})$ wherein

- i. $-28 \leq b_1 \leq -22$ preferably $-26 \leq b_1 \leq -25$
- ii. $13 \leq b_2 \leq 19$ preferably $15 \leq b_2 \leq 17$
- 5 iii. $0.05 \leq b_3 \leq 0.15$ preferably $0.08 \leq b_3 \leq 0.12$
- iv. $0.9 \leq b_4 \leq 1.4$ preferably $1.0 \leq b_4 \leq 1.2$
- v. $-4.4 \leq b_5 \leq -4.1$
- vi. $2.4 \leq b_6 \leq 2.7$ preferably $2.5 \leq b_6 \leq 2.6$
- vii. $6.0 \leq b_7 \leq 6.4$ preferably $6.2 \leq b_7 \leq 6.3$
- 10 viii. $-0.8 \leq b_8 \leq -0.4$ preferably $-0.7 \leq b_8 \leq -0.5$
- ix. $1.0 \leq b_9 \leq 1.1$
- x. $3.4 \leq b_{10} \leq 3.8$ preferably $3.6 \leq b_{10} \leq 3.7$
- xi. $-5.0 \leq b_{11} \leq -4.5$ preferably $-4.9 \leq b_{11} \leq -4.8$
- xii. $1.0 \leq b_{12} \leq 1.2$ preferably $1.05 \leq b_{12} \leq 1.15$.

15

10. The device of claim 9, wherein the logistic function is $-25.98652 + 16.00374 \times \text{Log}(\text{Alpha2Macroglobulin (g/l)}) + 0.10067 \times \text{Age (in years)} + 1.12881 \times \text{Log}(\text{ALT, IU / l}) - 4.24187 \times \text{ApoA1 (g/l)} + 2.55422 \times \text{Log}(\text{AST, IU / l}) + 6.22308 \times \text{Log}(\text{Bilirubin } (\mu\text{mol/l})) + 0.59340 \times \text{Log}(\text{CT, mmol/l}) + 1.07838 \times \text{Sex (female=0, male=1)} + 3.64357 \times \text{Log}(\text{GGT (IU/l)}) - 4.86167 \times \text{Log}(\text{Haptoglobin (g/l)}) + 1.11641 \times \text{Log}(\text{TG, mmol/l})$.
- 20


11. A method for obtaining a logistic function that can be used in a non-invasive diagnosis test for detecting NASH in a patient, wherein said logistic function combines the values of the concentration of biochemical markers in the serum of said patient, comprising the steps of:
- 25

- a) classifying patients of a cohort of patients into different groups according to the presence of NASH as determined by analysis of liver biopsy, whereas a patient is classified as having NASH if he
 - 30 i. has at least one factor of the metabolic syndrome, and not any other chronic or acute liver disease and
 - ii. presents hepatocyte ballooning or lobular activity (at least grade 1 each or at least grade 2 for one)
 - b) identifying, among the biochemical markers, the value of which has been measured, the ones which differ significantly between these groups by unidimensional analysis
- 35

- 5 c) performing a logistic regression analysis to assess the independent
discriminative value of these markers identified in step b) for the
diagnosis of NASH
- d) constructing the logistic function by combination of these identified
independent factors.
12. The method of claim 11, wherein the factor of metabolic syndrome is
selected from the group consisting of abdominal obesity, high serum
triglycerides (without treatment), low high-density lipoprotein (HDL)
10 cholesterol level (without treatment), elevated blood pressure and one of
the group consisting of elevated fasting plasma glucose, insulin resistance,
and prediabetes.
13. The method of claim 11 or 12, wherein the biochemical markers the
15 concentration of which is measured are chosen in the group consisting of
 α 2-macroglobulin, AST (aspartate aminotransferase), ALT (alanine
aminotransferase), GGT (gammaglutamyl transpeptidase), total bilirubin,
haptoglobin, apoA1, triglycerides, total cholesterol, fasting glucose, γ -
globulin, albumin, α 1-globulin, α 2-globulin, β -globulin, IL10, TGF- β 1,
20 apoA2, apoB, cytokeratin 18, platelets number, prothrombin level,
hyaluronic acid, urea, N-terminal of type III pro-collagen, Tissue inhibitor
metalloproteinase type-1 (TIMP-1), type IV collagen (Coll IV) and
osteoprotegerin.
14. The method of any one of claims 11 to 13, wherein the logistic function
25 further includes at least one other variable chosen in the group consisting of
gender, age and BMI of the patient.
15. The method of any one of claims 11 to 13, wherein the logistic function
30 does not comprise BMI and/or fasting glucose.

1 / 3

Steatosis → Ballooning → Lobular Inflammation: Diagnosis



From Bedossa et al, 2014

Figure 1

2 / 3

Features of SAF scoring system			NASH definitions			
Steatosis	Activity (SAF score)		Original	Extensions		
1%						
Steatosis not required						B2 or L2 accepted
	Ballooning	Lobular Inflammation	V1-S5	V2-S1	V3-noS- B1L1	V4-noS- B0L2- B2L0
3 levels	3 levels	3 levels				
0%	0	0	0	0	0	0
0%	0	1	0	0	0	0
0%	0	2	0	0	0	1
0%	1	0	0	0	0	0
0%	1	1	0	0	1	1
0%	1	2	0	0	1	1
0%	2	0	0	0	0	1
0%	2	1	0	0	1	1
0%	2	2	0	0	1	1
1-4%	0	0	0	0	0	0
1-4%	0	1	0	0	0	0
1-4%	0	2	0	0	0	1
1-4%	1	0	0	0	0	0
1-4%	1	1	0	1	1	1
1-4%	1	2	0	1	1	1
1-4%	2	0	0	0	0	1
1-4%	2	1	0	1	1	1
1-4%	2	2	0	1	1	1
>=5%	0	0	0	0	0	0
>=5%	0	1	0	0	0	0
>=5%	0	2	0	0	0	1
>=5%	1	0	0	0	0	0
>=5%	1	1	1	1	1	1
>=5%	1	2	1	1	1	1
>=5%	2	0	0	0	0	1
>=5%	2	1	1	1	1	1
>=5%	2	2	1	1	1	1

Figure 2





Figure 3

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/073241

A. CLASSIFICATION OF SUBJECT MATTER

INV. G01N33/576 G01N33/92 G06F19/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G01N G06F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	POYNARD THIERRY ET AL: "The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis", COMPARATIVE HEPATOLOGY, BIOMED CENTRAL LTD, GB, vol. 4, no. 1, 23 December 2005 (2005-12-23), page 10, XP021008456, ISSN: 1476-5926, DOI: 10.1186/1476-5926-4-10 Discussion; tables ----- -/--	1-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

9 October 2017

Date of mailing of the international search report

23/10/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Vogt, Titus

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2017/073241

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	POYNARD THIERRY ET AL: "Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholic steato hepatitis in patients with non-alcoholic fatty liver disease", BMC GASTROENTEROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 6, no. 1, 10 November 2006 (2006-11-10), page 34, XP021022807, ISSN: 1471-230X, DOI: 10.1186/1471-230X-6-34 tables	1-15
X	----- WO 2006/082522 A1 (ASSIST PUBL HOPITAUX DE PARIS [FR]; POYNARD THIERRY [FR]) 10 August 2006 (2006-08-10)	4-6,9-15
Y	claims	1-15
X	----- WO 2006/103570 A2 (ASSIST PUBL HOPITAUX DE PARIS [FR]; POYNARD THIERRY [FR]) 5 October 2006 (2006-10-05)	4-6,9-15
Y	claims	1-15
Y	----- THIERRY POYNARD ET AL: "Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data", PLOS ONE, vol. 7, no. 3, 14 March 2012 (2012-03-14), page e30325, XP055327259, DOI: 10.1371/journal.pone.0030325 Supporting info; abstract	1-15
Y	----- M. MUNTEANU ET AL: "Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., vol. 44, no. 8, 23 August 2016 (2016-08-23), pages 877-889, XP055327194, GB ISSN: 0269-2813, DOI: 10.1111/apt.13770 Supplementary Material; tables -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/073241

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006082522 A1	10-08-2006	AT 412905 T	15-11-2008
		BR PI0606840 A2	09-03-2010
		CA 2596682 A1	10-08-2006
		CN 101175998 A	07-05-2008
		EP 1856536 A1	21-11-2007
		JP 2008529030 A	31-07-2008
		MA 29282 B1	01-02-2008
		US 2006173629 A1	03-08-2006
		US 2009111132 A1	30-04-2009
		WO 2006082522 A1	10-08-2006

WO 2006103570 A2	05-10-2006	EP 1846862 A2	24-10-2007
		US 2006172286 A1	03-08-2006
		US 2008145864 A1	19-06-2008
		WO 2006103570 A2	05-10-2006
